Multi-drug chemotherapy for pancreatic cancer

4267 Background: G-FLIP, a low dose, multi-drug regimen, produced an objective response and stable disease rate of (7+6/34) 38% and overall median survival (MST) of 10.3 additional mos on adding 80 mg/M2 of Irinotecan to a ‘failed’ q2 wk Gemzar-Fluorouracil-Cisplatin regimen (The Oncologist 6:488 2001). Methods: Subsequently, G-FLIP was used for all non-adjuvant applications. Interim analysis found overall MST of 15–18 mos (Bruckner et al, ICACT 2001; 2003). In part, treatment after G-FLIP ‘failure’ substituted Taxotere (Xeloda) or Methotrexate for Irinotecan in multi-drug regimens with a 20% rate of objective response (Bruckner et al, ASCO, San Francisco, 2004.) Currently, all new patients (pts) were updated. Results: Overall MST for 102 intent-to-treat pts from diagnosis is 15.5 mos, and 28% at 2 yrs. Survival of these new pre-registered pts matches MST of ideally resected pts in the pre-G-FLIP period (Snady et al, Cancer, 2001), in spite of currently excluding the successfully resected and including th...